Applications of microRNAs in the diagnosis and prognosis of lung cancer

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 3, 2012, Pages 197-207

  Shen, Jun ^a   Jiang, Feng ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Diagnosis; Lung cancer; MiRNAs; Prognosis

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; PEMETREXED;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; EARLY DIAGNOSIS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; MICROARRAY ANALYSIS; MOLECULAR GENETICS; OUTCOME ASSESSMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 84860238222     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.672970     Document Type: Review

References (74)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Gao W, Xu J, Shu YQ. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer. Expert Rev Respir Med 2011;5:699-709
3. Midthun DE. Screening for lung cancer. Clin Chest Med 2011;32:659-68
4. Reddy C, Chilla D, Boltax J. Lung cancer screening: a review of available data and current guidelines. Hosp Pract (Minneap) 2011;39:107-12
5. Lin PY, Yang PC. Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med 2011;3:436-7
6. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-9
7. Van't Westeinde SC, van Klaveren RJ. Screening and early detection of lung cancer. Cancer J 2011;17:3-10
8. Fanini F, Vannini I, Amadori D, et al. Clinical implications of microRNAs in lung cancer. Semin Oncol 2011;38:776-80
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
10. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9
11. Alexiou P, Maragkakis M, Papadopoulos GL, et al. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics 2009;25:3049-55
12. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8
14. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006
15. Wang QZ, Xu W, Habib N, et al. Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets 2009;9:572-94
16. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273-81
17. Cho WC. MicroRNAs as therapeutic targets for lung cancer. Expert Opin Ther Targets 2010;14:1005-8
18. Cho WC. Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer. Expert Rev Mol Diagn 2011;11:763-6
19. Skrzypski M, Dziadziuszko R, Jassem J. MicroRNA in lung cancer diagnostics and treatment. Mutat Res 2011;717:25-31
20. Cherni I, Weiss GJ. miRNAs in lung cancer: large roles for small players. Future Oncol 2011;7:1045-55
21. Markou A, Liang Y, Lianidou E. Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer. Clin Chem Lab Med 2011;49:1591-603
22. Brase JC, Wuttig D, Kuner R, et al. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010;9:306
23. World Health Organization. Histological Typing of Lung Tumors. 2nd edition. World Health Organization; Geneva, Switzerland: 1981
24. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumors. Eur Respir J 2001;18:1059-68
25. Stang A, Pohlabeln H, Muller KM, et al. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based casecontrol study. Lung Cancer 2006;52:29-36
26. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
27. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98
28. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-19
29. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030-7
30. Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010;16:430-41
31. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009;10:116-25
32. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-9
33. Liu XG, Zhu WY, Huang YY, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012, In press
34. Vosa U, Vooder T, Kolde R, et al. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer 2011;50:812-22
35. Tan X, Qin W, Zhang L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011;17:6802-11
36. Seike M, Goto A, Okano T, et al. MiR-21 is an EGFR-regulated antiapoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009;106:12085-90
37. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009;69:5776-83
38. Dacic S, Kelly L, Shuai Y, et al. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol 2010;23:1577-82
39. Xing L, Todd NW, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol 2010;23:1157-64
40. Yu L, Todd NW, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010;127:2870-8
41. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011;91:579-87
42. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-86
43. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009;10:42-6
44. Roth C, Kasimir-Bauer S, Pantel K, et al. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 2011;5:281-91
45. Foss KM, Sima C, Ugolini D, et al. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011;6:482-8
46. Chen X, Hu Z, Wang W, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012;130:1620-8
47. Keller A, Leidinger P, Gislefoss R, et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011;8:506-16
48. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011;108:3713-18
49. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503
50. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011;11:374
51. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-9
52. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9
53. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 2010;5:220-8
54. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6
55. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509
56. Inamura K, Togashi Y, Nomura K, et al. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer 2007;58:392-6
57. Watanabe K, Emoto N, Hamano E, et al. Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer 2012;In press
58. Arora S, Ranade AR, Tran NL, et al. MicroRNA-328 is associated with (nonsmall) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011;129:2621-31
59. Navarro A, Diaz T, Gallardo E, et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol 2011;103:411-15
60. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57
61. Patnaik SK, Kannisto E, Knudsen S, et al. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010;70:36-45
62. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009;69:5776-83
63. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011;17:1875-82
64. Wang ZX, Bian HB, Wang JR, et al. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol 2011;104:847-51
65. Donnem T, Lonvik K, Eklo K, et al. Independent and tissue-specific prognostic impact of miR-126 innonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011;117:3193-200
66. Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011;8:125-31
67. Voortman J, Goto A, Mendiboure J, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010;70:8288-98
68. Lee JH, Voortman J, Dingemans AM, et al. MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One 2011;6:e21300
69. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28:1721-6
70. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10:297-308
71. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-18
72. Del Vescovo V, Cantaloni C, Cucino A, et al. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011;35:268-75
73. Du L, Schageman JJ, Irnov I, et al. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 2010;29:75
74. Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 2012;130:1378-86